Immunology

HSCI scientists advance Type 1 diabetes therapy by protecting cells from immune attack and stress The stem cell-based approach to treating Type 1 diabetes (T1D) is successfully being tested in the clinic, using a transplant of stem cell-derived beta cells...

Douglas Melton, Co-Director of the Harvard Stem Cell Institute (HSCI), has received a financial grant from His Highness Sheikh Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi. The grant will bolster HSCI research focusing on accelerating gene...

Harvard and MIT researchers identify possible mechanism linking autism and intestinal inflammation Many people with autism spectrum disorders also experience unusual gastrointestinal inflammation, but thus far scientists have not established whether and...

Cells in our body bristle with sugars known as glycans that other cells can recognize via specialized receptors. By attaching to and modifying proteins and fats, glycans influence how proteins fold, how cues are sent between cells, and other cell-to-cell...

HSCI Principal Faculty member Jose Ordovas-Montanes has received an early-career award from the New York Stem Cell Foundation (NYSCF). He has been named a NYSCF – Robertson Investigator, which recognizes cutting-edge research with the potential to...

HSCI scientists show that engineered “5-module CAR” T cells target harmful T cells responsible for type 1 diabetes Researchers have engineered a specialized type of T cell that can specifically target and eliminate harmful T cells, particularly the...

HSCI scientists identify gut-brain connection in ALS By Jessica Lau HSCI scientists have identified a new gut-brain connection in the neurodegenerative disease amyotrophic lateral sclerosis, or ALS. The researchers found that in mice with a common ALS...

Cancer immunologists and biological engineers at Harvard unite to fight therapy-resistant cancers A new NIH-funded Immuno-Engineering to Improve Immunotherapy (i3) Center at Harvard University sets out to create new anti-cancer immunotherapies using...

New microgel encapsulation method paves the way for more efficient cell therapies Bone marrow transplants have become a standard treatment for a range of blood cancers and diseases, but many transplants fail due to rejection by the patient’s immune system...

Sana Biotechnology licenses innovative immune-silent stem cell technology developed though Harvard’s Blavatnik Biomedical Accelerator Protecting transplanted cells from immune attack is a serious challenge. As with any organ transplant, cell lines derived...